Drug Trial Radar · NCT00158041
Subcutaneous Amifostine Safety Study
Last checked: Nov 20, 2026Latest source record: Sep 12, 2005 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
452
Actual
Start
Jan 2002
Primary completion
Not stated
Study completion Jan 2005
Sponsor
- Lead sponsor
- Mt. Sinai Medical Center, MiamiAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- MedImmune LLC
- First posted
- Sep 12, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Amifostine is a radioprotective drug which is approved by the US FDA for administration prior to each radiation treatment using the intravenous route. The study evaluated the safety of amifostine administered subcutaneously. The four targeted toxicities were nausea/vomiting, hypotension, generalized skin rash, and injection-site skin reactions.
Conditions
- Head and Neck Cancer
- Lung Cancer
- Lymphoma
Interventions
Amifostine administered subcutaneouslyDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of nausea/vomiting
- Incidence of hypotension
- Incidence of generalized skin rash
- Incidence of injection-site skin toxicity
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mt. Sinai Medical Center
Miami Beach, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.